Based on the promising preclinical data described above, several clinical trials have evaluated the effectiveness of combining endocrine and HER2-targeted therapies in the neoadjuvant, extended adjuvant, and advanced/metastatic breast cancer settings (Table 2)7,35,37,38,41,65–97. Here, ERBB2 is linked to breast carcinoma.